Genedata Biopharma Platform Adopted by Genmab to Streamline Biotherapeutics R&D Operations
Genedata E2E software solution to increase speed and efficiency of discovery and development of Genmab’s next-generation cancer therapies
July 9, 2019
Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced that Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer, has adopted the Genedata Biopharma Platform to support their global oncology programs.
“We are excited to partner with Genmab, a pioneer in the field of innovative biopharmaceuticals, to digitalize biopharma R&D workflows,” said Dr. Othmar Pfannes, CEO of Genedata. “We are delighted that Genmab will use our enterprise platform as the foundation to enable them to develop next-generation biotherapeutics to improve the lives of patients worldwide.”
“To support our vision of transforming cancer treatment, we are excited to implement the Genedata Biopharma Platform as a central integrated data backbone to streamline the capture, integration, democratization, and analysis of increasingly complex and diverse data types across Genmab’s discovery and clinical workflows. This will help us make nimble, data-informed, decisions as we advance our portfolio,” said Hisham Hamadeh, Ph.D., Vice President, Global Head of Data Sciences, at Genmab.
The Genedata Biopharma Platform will support Genmab’s global R&D operations, including Genmab’s proprietary next-generation antibody technology platforms DuoBody®, HexaBody® and other Genmab-specific discovery platforms.
Fully Integrated Workflow and Analysis Platform
The Genedata Biopharma Platform is a state-of-the-art enterprise E2E platform that is designed to support high-throughput processes for biopharmaceutical R&D and consists of the components Genedata Biologics®, Genedata Bioprocess®, Genedata Expressionist®, Genedata Profiler®, Genedata Screener®, and Genedata Selector®. The platform collects, integrates, processes, and analyzes data from drug candidates and patient samples, in particular assay and analytics data, and provides access to the data across the entire biopharmaceutical R&D process, from lead discovery through candidate development to translational and clinical science. The Genedata Biopharma Platform harmonizes and automates time-consuming workflows including mass spectrometry, next generation sequencing, clinical outcomes, and a diversity of other data types. In this manner, the ecosystem ensures data quality and integrity, automates R&D processes to reduce timelines, and drives next-generation business intelligence.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®, DuoBody®, HexaBody®
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.